Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Sequenom
So what: The test will be available in 20 different U.S. cities today, two years after a previous attempt to bring it to market experienced a setback because employees mishandled sensitive research data. A clinical validation study showed that the blood test is able to detect 99.1% of all positive cases of Trisomy 21, the genetic defect that commonly causes Down syndrome.
Now what: Sequenom utilizes a blood test from a pregnant woman, compared to the current method of amniocentesis, inserting a needle into the uterus to sample amniotic fluid. Amniocentesis carries the risk of miscarriage and the new test can reduce procedure-related losses by up to 96% while also boasting high accuracy. Sequenom is targeting 750,000 tests in the U.S. annually.
Interested in more info on Sequenom? Add it to your watchlist by clicking here.
Fool contributor Evan Niu holds no position in any company mentioned. Click here to see his holdings and a short bio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.